How to make steatotic livers suitable for transplantation

Liver Transplantation

Volumn 13, Issue 4, 2007, Pages 480-482

  Alwayn, Ian P J ^a   Porte, Robert J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

CRYOPRESERVATION; DIABETES MELLITUS; DISEASE MODEL; EDITORIAL; FATTY LIVER; FOLLOW UP; HUMAN; LIVER FAILURE; LIVER FUNCTION; LIVER ISCHEMIA; LIVER TRANSPLANTATION; LIVING DONOR; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXYGENATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REPERFUSION INJURY; TREATMENT INDICATION;

ANIMALS; FATTY LIVER; HUMANS; LIVER TRANSPLANTATION; MODELS, ANIMAL; PATIENT SELECTION; TISSUE AND ORGAN HARVESTING; TISSUE DONORS;

EID: 34247208635     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21026     Document Type: Editorial

References (25)

1. Cameron AM, Ghobrial RM, Yerzis H, Farmer DG, Lipshutz GS, Gordon SA, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006;243:748-753.
2. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9: 651-663.
3. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004;3:63-65.
4. Soejima Y, Shimada. M, Suehiro T, Kishikawa K, Yoshizumi T, Hashimoto K, et al. Use of steatotic grafts in living-donor liver transplantation. Transplantation 2003;762: 344-348.
5. Mor E, Klinmalm GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, et al. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 1992;53:383-386.
6. Imber CJ, St Peter SD, Lopez I. Current practice regarding the use of fatty livers: a trans-Atlantic survey. Liver Transpl 2002;8:545-549.
7. Todo S, Demetris AJ, Makowka L, Teperman L, Podesta L, Shaver T, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989; 47:903-905.
8. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003;9:500-505.
9. Bessems M, Doorschodt BM, Kolkert JL, et al. Preservation of steatotic livers: a comparison between cold storage and machine perfusion preservation. Liver Transpl 2007; 13:497-504.
10. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006;12:523-534.
11. Alwayn IP, Javid PJ, Gura KM, Nose V, Ollero M, Puder M. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1c suppression or by correcting essential fatty acid deficiency. Hepatology 2004:39: 1176-1177.
12. Mats CA, Perez RM, Pacheco MS, Figueiredo-Mendes CG, Lopes-Neto E, Oliveira EB Jr, et al. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol 2006;21:1236-1239.
13. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-194.
14. Guglielmi FW, Boggio-Bertinet D, Frederico A, Forte GB, Guglielmi A, Loguercio C, et al. Total parenteral nutrition-related gastroenterological complications. Dig Liver Dis 2006;38:623-642.
15. Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, Gura KM et al. Inhibition of matrix metalloproteinases increases PPAR-{alpha} and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol 2006;Epub.
16. Inoue M, Ohtake K, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 2005;336:215-222.
17. Farrel GC. Signalling links in the liver: knitting SOCS with fat and inflammation. J Hepatol 2005;43:193-196.
18. Horton JD, Shinomura I, Ikemoto S, Bashmakov Y, Hammer RE. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J Biol Chem 2003;278:36652-36660.
19. Leclerq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004;41:926-934.
20. Harrison SA. New treatments for nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2006:8:21-29.
21. Cheng YF, Chen CL, Lai CY, Chen TY, Huang TL, Lee TY, et al. Assessment of donor fatty livers for liver transplantation. Transplantation 2001;71:1221.
22. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997;64: 248-251.
23. Alwayn IP, Gura K, Nose V, Zausche B, Javid P, Garza J, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005;57:445-452.
24. Kim SH, Lee JM, Han JK, Lee JY, Lee KH, Han CJ, et al. Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging - correlation with histopathologic findings. Radiology 2006;240:116-129.
25. Adani GL, Baccarani U, Sainz-Barriga M, Lorenzin D, Bresadola V, Risaliti A, et al. The role of hepatic biopsy to detect macrovacuolar steatosis during liver procurement. Transplant Proc 2006;38:1404-1406.